Abstract: This disclosure describes an unmanned aerial vehicle (“UAV”) configured to autonomously deliver items of inventory to various destinations. The UAV may receive inventory information and a destination location and autonomously retrieve the inventory from a location within a materials handling facility, compute a route from the materials handling facility to a destination and travel to the destination to deliver the inventory.

Abstract: A network adapter includes a network interface, a bus interface, a hardware-implemented data-path and a programmable Data-Plane Accelerator (DPA). The network interface is to communicate with a network. The bus interface is to communicate with an external device over a peripheral bus. The hardware-implemented data-path includes a plurality of packet-processing engines to process data units exchanged between the network and the external device. The DPA is to expose on the peripheral bus a User-Defined Peripheral-bus Device (UDPD), to run user-programmable logic that implements the UDPD, and to process transactions issued from the external device to the UDPD by reusing one or more of the packet-processing engines of the data-path.

Abstract: Aspects of the subject technology provide improved techniques for gesture recognition. Improved techniques may include detecting and/or classifying an interaction between the body part and another object in a scan of the body part, and then controlling recognition of a gesture based on the interaction. In an aspect, recognition parameters may be selected based on the interaction classification that disable recognition of one or more gestures while not disabling recognition of other gestures.

Abstract: Certain aspects of the present disclosure provide techniques for slot preconfiguration for coverage enhancement and power saving. An example method performed by a UE includes processing one or more synchronization signals in a first slot according to a first configuration of slot parameters, wherein the synchronization signals are used for at least one of time or frequency tracking, receiving, from a network entity, a second configuration of slot parameters, and processing a physical downlink control channel (PDCCH) in a second slot according to the second configuration of slot parameters, wherein the second slot occurs within a configured slot duration that is offset in time from the first slot.

Abstract: A system includes a bus interface and circuitry. The bus interface is configured to communicate with an external device over a peripheral bus. The circuitry is configured to support a plurality of widgets that perform primitive operations used in implementing peripheral-bus devices, to receive a user-defined configuration, which specifies a user-defined peripheral-bus device as a configuration of one or more of the widgets, and to implement the user-defined peripheral-bus device toward the external device over the peripheral bus, in accordance with the user-defined configuration.

Abstract: An aqueous gel composition comprising a) water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90% by weight of the composition, and b) a local anaesthetic agent or an analgesic agent, for use as a local anaesthetic or analgesic. The aqueous gel shows transparency, lubricity, stringiness, elongation, extensiveness, and cohesiveness while being devoid of taste and smell and non-tacky or non-sticky.

Abstract: The present invention relates to a structure for the controlled release of at least one active substance, where the structure comprises the active substance and a cellular solid material comprising cellulose nanofibers (CNF). The structure has a density of less than 1000 kg/m3, and the cellular solid material comprises closed cells. The invention further relates to a method for preparing the structure; as well as the use of the structure.

Abstract: An aqueous gel composition comprising a) water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90% by weight of the composition, and b) a local anaesthetic agent or an analgesic agent, for use as a local anaesthetic or analgesic. The aqueous gel shows transparency, lubricity, stringiness, elongation, extensiveness, and cohesiveness while being devoid of taste and smell and non-tacky or non-sticky.

Abstract: The present invention relates to a GI-cleansing composition comprising i) one or more gelling or swelling agents, ii) one or more laxative agents, iii) one of more taste-improving agents, and iv) water.

Abstract: A syringe (1) for mixing and ejecting an active pharmaceutical ingredient is disclosed. The syringe (1) comprises a syringe body (2) defining a first lumen (8), a first plunger (4) arranged movably in said first lumen (8), said first plunger (4) being hollow, thereby defining a second lumen (9) being separated from the first lumen (8), and a second plunger (5) arranged movably in said second lumen (9). A liquid diluent is contained in one of the first lumen (8) and the second lumen (9), and an active pharmaceutical ingredient is contained in the other of the first lumen (8) and the second lumen (9). The second plunger (5) is movable in such a manner that the active pharmaceutical ingredient and the liquid diluent are brought together, e.g.

Abstract: A oral pharmaceutical composition for controlled release of an opioid from a pharmaceutical composition is described that comprises (i) an erodible matrix composition comprising a mixture of (a) a polymer or a mixture of polymers (b) an opioid, and optionally, (c) one or more pharmaceutically acceptable excipients; and (ii) a single, substantially insoluble in and impermeable coating having two openings exposing at least one surface of the matrix, and comprising one or more polymers. The composition exhibits controlled release of the opioid by erosion of the matrix and exhibits a zero order release profile wherein about 75% w/w of the opioid is released from the composition within 4-10 hours when tested in a dissolution test as described herein.

Abstract: A syringe for mixing and ejecting an active pharmaceutical ingredient is disclosed. The syringe is designed in such a manner that it is ensured that substantially all of the mixed drug is ejected, and in such a manner that an active pharmaceutical ingredient can be lyophilized directly into the syringe. The syringe comprises a syringe body, a first plunger arranged movably inside the syringe body and a second plunger arranged movably inside the first plunger. In one aspect the second plunger comprises a first plunger part and a second plunger part, and the first and second plunger parts are adapted to cooperate to collapse the cavity of the first plunger. In a second aspect the cavity of the first plunger has a first diameter at a distal end and a second diameter at a proximal end, the first diameter being smaller than the second diameter.

Abstract: A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and, optionally, c) one or more pharmaceutically acceptable excipients, and ii) a coating.

Abstract: An aqueous gel composition comprising a) water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90% by weight of the composition, and b) a local anaesthetic agent or an analgesic agent, for use as a local anaesthetic or analgesic. The aqueous gel shows transparency, lubricity, stringiness, elongation, extensiveness, and cohesiveness while being devoid of taste and smell and non-tacky or non-sticky.

Abstract: A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals.

Abstract: Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof.

Abstract: A composition for controlled release of an opioid from a pharmaceutical composition, the method comprises controlling the release of at least one opioid into an aqueous medium by erosion of at least one surface of a pharmaceutical composition comprising I) a matrix composition comprising a) polymer or a mixture of polymers, b) an opioid and, optionally, c) one or more pharmaceutically acceptable excipients, and (i) a coating. The matrix composition has a conus-like shape so the surface area exposed to the aqueous medium increases at least during initial erosion of the matrix composition, and the dissolution of the opioid—when tested in a Dissolution Test as described herein with or without application of sinkers—results in a zero order release of at least 80% of the opioid contained in the composition. Such compositions are especially suitable for controlled release of an opioid to obtain a delayed pead concentration and a prolonged therapeutically effective plasma concentration upon oral administration.

Abstract: Described are controlled release oral pharmaceutical composition comprising an erodible matrix composition comprising a polyethylene oxide, a therapeutically effective amount of an opioid or a pharmaceutically acceptable salt, complex, solvate or anhydrate thereof, or a mixture thereof and, optionally, one or more pharmaceutically acceptable excipients, and a coating on the matrix composition, wherein the coating has at least one opening exposing a surface of an end portion of the matrix composition, thereby allowing controlled release of the opioid by erosion of the matrix surface, wherein the composition exhibits zero order release of at least 80% of the opioid contained in the composition. The matrix may have a cylindrical shape having a long axis and a conus-shaped end portion having a largest diameter and a smallest diameter, such that the surface area exposed increases during erosion of the conus-shaped end portion.

Abstract: A microfluidic system comprises a liquid reservoir containing a liquid and having a capillary pipe opening. The microfluidic system also comprises an elongated bar having a proximal end contacting the liquid reservoir in the opening, a distal section at which a micro-droplet is formed, and a middle section continuously maintaining thereon a liquid bridge between the reservoir and the micro-droplet.

Abstract: Disclosed herein is a ready-to-use injection device for single use and a container for such device. The container comprises at least one first closed chamber for containine an active substance and optionally a second closed chamber for containing a quid substance comprising an active substance or a solvent. The two chambers are separated by a separation wall which is impermeable and breakable upon exertion of an external force, resulting in enhanced mixing of the substances contained in the device with a minimal formation of air bubbles. The present injection device is safe and particularly well suited for enhanced mixing of pharmaceutically active compositions to be injected in patients and can be used for vaccination programs.